Price T Rowe Associates Inc Karuna Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $125 Million - $246 Million	-773,251 Reduced 28.27%	1,961,587 $621 Million
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $12.1 Million - $16 Million	73,346 Added 2.76%	2,734,838 $462 Million
Q2 2023 Aug 14, 2023	BUY	$176.32 - $240.22 $31.7 Million - $43.2 Million	179,932 Added 7.25%	2,661,492 $577 Million
Q1 2023 May 15, 2023	BUY	$161.33 - $204.36 $19.1 Million - $24.2 Million	118,256 Added 5.0%	2,481,560 $451 Million
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $28.2 Million - $34.8 Million	147,158 Added 6.64%	2,363,304 $464 Million

Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $23.7 Million - $53.1 Million	191,307 Added 9.45%	2,216,146 $498 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $8.12 Million - $12.4 Million	-86,395 Reduced 4.09%	2,024,839 $256 Million
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $15.4 Million - $20.6 Million	155,868 Added 7.97%	2,111,234 $268 Million
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $12.7 Million - $18.3 Million	114,735 Added 6.23%	1,955,366 $256 Million
Q3 2021 Nov 15, 2021	BUY	$101.2 - $125.87 $5.81 Million - $7.22 Million	57,363 Added 3.22%	1,840,631 $225 Million
Q2 2021 Aug 16, 2021	BUY	$107.45 - $135.95 $9.94 Million - $12.6 Million	92,493 Added 5.47%	1,783,268 $203 Million
Q1 2021 May 17, 2021	BUY	$95.46 - $133.08 $25.5 Million - $35.5 Million	266,614 Added 18.72%	1,690,775 $203 Million
Q4 2020 Feb 16, 2021	BUY	$75.23 - $109.23 $107 Million - $156 Million	1,424,161 New	1,424,161 $145 Million

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.